The endothelium of coronary arteries has been identified as an important organ locally regulating coronary perfusion and cardiac function by paracrine secretion of nitric oxide (NO) and other vasoactive mediators. Therefore, the established organ procurement in cardiac transplantation using hypothermic storage solutions designed to preserve myocytes but not endothelial cells has to be critically discussed. Heart transplantation is a prestigious high-end treatment for end-stage heart failure patients with promising survival rates: 84% one-year and 65% five-year survival. However, these survival rates are still far from being satisfying requiring further research in organ preservation and perioperative management. This review will focus on possible strategies to improve donor and recipient management in regard to a functional endothelium and NO. The following topics will be addressed: (1) NO and ischemia/reperfusion, to understand the mechanisms that lead to NO depletion and its consequences. (2) NO and hypothermia, to understand the effects of hypothermia on the endothelium. (3) Current status of donor and recipient management, to describe the strategies used today. (4) Possible new approaches: NO-scavenging and NO-substitution, to describe the recent research that is performed in this area including some of our own results. (5) Outlook in donor and recipient management, to give possible new directions, deducted from our current knowledge.
Introduction
Nitric oxide (NO) releasing agents have a long lasting history in cardiovascular medicine. First reports date back to 1879, when W. Murrell reported that orally administered nitroglycerine relieves angina pectoris [36] . However, the exact mechanisms of its biological action remained unclear.
In 1980, Furchgott and Zawadzki described a potent, endogenous vasodilator [14] . Initially referred to as endothelial-derived-relaxing-factor (EDRF), it took seven more years to identify NO as the primary EDRF [13] . In the forthcoming years, research in NO boomed: It became clear that NO is a central regulator in the cardiovascular system.
This review provides an overview about possible implications of NO substitution for both donor and recipient management in cardiac transplantation.
NO in ischemia/reperfusion
Re-establishing blood flow to ischemic tissues or organs (reperfusion) is an essential step in many surgical procedures [30] . However, especially after prolonged ischemia, reperfusion can lead to changes in vascular tone and an increase in microvascular permeability causing tissue reperfusion edema [57] . These damages are referred to as ischemia/reperfusion (I/R) injury. The consequences of such an injury are massive edema formation and tissue destruction [4, 18] .
Constitutive eNOS plays a fundamental role in the pathogenesis of I/R injury. The onset of ischemia leads to elevated intracellular calcium ion concentrations mediated by increased levels of catecholamines. These increased calcium concentrations activate eNOS to generate nitric oxide and consequently reactive oxygen species and cytotoxic substances [22] . Studies on I/R injury strongly suggest a correlation between initially high NO production during ischemia followed by increasing release of O `( decrease in net NO production) and increasing injury to the endothelium, constriction of vessels, and edema formation. I/R injury is initiated by a massive burst of NO production after ischemia, which depletes local Larginine concentrations, followed by high production of O `a fter reperfusion and consequently high production of peroxynitrite. The formation of excessive local peroxynitrite concentrations and consequent cleavage products during the initial phase of reperfusion is deleterious. Three of these cleavage products (hydroxyl free radical, nitrogen dioxide free radical, and nitronium cation) are among the most reactive and damaging species and may be major contributors to the severe I/R damage [22] .
Endothelial dysfunction is an important factor during and after cardiac transplantation. Both I/R and hypothermia induce endothelial dysfuntion, more commonly known as endothelial stunning: as NO production decreases, vasoconstrictive compounds dominate. This leads to no-reflow and finally to organ failure. In the heart, this temporary failure is called "myocardial stunning", which can be characterized as a mechanical dysfunction that persists after reperfusion despite the absence of irreversible damage and despite restoration of normal or near-normal coronary blood flow. Implying that this post ischemic dysfunction is fully reversible, no matter how severe or prolonged [5] .
NO and hypothermia
Hypothermia between 4°C and 8°C is commonly used for organ storage until transplantation. The solutions used for this purpose have specific constituents that facilitate a rapid secession of the electrical activity of the organ. They need two meet the following requirements: (1) Provision of a physical and biochemical environment that maintains viability of the structural components of the tissue during hypothermic metabolic arrest and (2) Minimization of the effects of reperfusion injury.
Though cold ischemic storage is a commonly used and effective method to preserve organs, certain processes are activated that ultimately can be deleterious to the preserved organ. These include: cellular swelling, extracellular edema, cellular acidosis, depletion of metabolic substrate, reperfusion injury, calcium overload and endothelial injury [24] .
Porcine coronary endothelial cells stored in an University of Wisconsin solution showed a significant decrease in eNOS activity after storage for more than 6 hours. However, there was no significant decrease stored only for one hour [47] .
Current status of donor and recipient management Donor management
The first step of many leading to successful heart transplantation is adequate organ preservation ensuring maintenance of organ viability and function. It is the major challenge to minimize damage to the heart during procurement, storage and implantation, as the heart is always exposed to ischemia and reperfusion during these procedures. The current clinical practice used in heart preservation is based on a single flush induction of cardioplegia and subsequent hypothermic storage in one of a number of storage solutions [66] . These solutions were designed to protect mainly the myocytes against hypothermic swelling, augment energy production on reperfusion, and ablate pathologic damage by reactive oxygen species formed during reperfusion [56] .
In this game, time still plays a major roll as the heart only tolerates 4-5 hours of ischemia -longer periods lead to a significant increase in acute and chronic organ failure. Consequences are those already described for endothelial stunning.
Besides ischemia, reperfusion and hypothermia there are many other different stimuli that can damage the endothelium during heart transplantation: for instance brain death and mechanical forces from cardioplegic solutions [36] .
Recipient management

Short-term management
Registry data from the International Society of Heart and Lung Transplantation shows that despite advances in perioperative management, right ventricular dysfunction accounts for 50% of all cardiac complications and 19% of all early deaths in patients after heart transplantation. There are several factors contributing to right ventricular dysfunction:
Pulmonary hypertension as a result of congestive heart failure is a major risk factor for morbidity and mortality following heart transplantation. In many centers preexisting pulmonary hypertension with a transpulmonary gradient over 15 mmHg or a pulmonary vascular resistance greater than 6-8 Woods units is a contraindication for heart transplantation.
During the intraoperative period the elevated pulmonary resistance is further worsened by cardiopulmonary bypass, transfusion of blood, heparin-protamin infusion and other metabolic factors. After a period of cold ischemia the right ventricle of the allograft is not adequately adapted to face a substantial rise in pulmonary vascular resistance [3] . Optimal right ventricular myocardial protection by cardioplegia is difficult due to anatomical limitations in the distribution of the coronary arteries.
Right ventricular failure results in its dilation, ischemia and decreased contractility, leading to a decreased pulmonary blood flow and leftward shift of the septum resulting in a lower LV filling and reduced systemic cardiac output. Treatment of this condition should include: preservation of the coronary perfusion through maintenance of the systemic blood pressure, optimization of the right ventricular preload, reduction of the right ventricular afterload and a limitation of pulmonary vasoconstriction.
Mechanical ways as the implantation of a right ventricular assist device or an extra-corporal membrane oxygenation (ECMO) [58] can be used to lower right ventricular workload. Pharmacologically, potent pulmonary vasodilators as prostaglandin E1 or prostacyclin can be used. However, systemic vasodilators bare the problem that they not only affect pulmonary circulation but also systemic circulation and thereby lower systemic blood pressure during this critical perioperative phase.
Inhaled NO has been shown to be a potent, rapidly acting and selective pulmonary vasodilator. Due to its short half life NO is inactivated directly in the lumen of the pulmonary vessels and exerts its action only on the endothelial and smooth muscle cells adjacent the alveolar unit. This is why no or only little effect on the systemic vascular resistance can be observed. However, due to its toxicity and formation of methemoglobin, NO and peroxynitrite, the use of inhaled NO should be carried out very carefully [64] .
Long-term management
In heart transplant recipients, the alloimmune response and metabolic abnormalities developing as a consequence of the immunosuppressive drugs have deleterious effects on the endothelium. This is not only affecting the early outcome after transplantation but also triggers graft atherosclerosis, which is the leading cause of death in patients surviving the first year after transplantation [62] .
NO seems to play a beneficial role in cardiac allograft vasculopathy. After transplantation, the heart and especially the coronary endothelial cells are subjected to hypercholesterolemia, hypertriglycerinemia, hyperhomocysteinemia, hyperglycemia and hypertension. All these conditions are associated with endothelial vasodilator dysfunction and mainly triggered by the use of cyclosporine or tacrolimus and steroids for immunosupression. The allograft coronary endothelial cells also serve as potent stimulators as well as targets of allogenic lymphocyte reactivity [65] .
The substitution of L-arginine after transplantation has shown to prevent neointimal hyperplasia in allograft coronary arteries via modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6 [34] . Substitution of NO via a liposome-mediated gene transfection of eNOS has shown to have beneficial effects in reducing ischemia-reperfusion injury. The liposomes complexed to the gene encoding eNOS were infused into the donor coronary circulation before transplantation. This resulted in an inhibition of NF-kB activation, adhesion molecule expression and the early infiltration of leukocytes [23] . Another novel strategy for the treatment of transplant vasculopathy could be the use of NO-donating aspirin (NCX 4040), which has shown beneficial effects on relaxation, cGMP formation and proliferation of vascular smooth muscle cells in vitro [53] . a liposome-mediated gene transfection of eNOS has shown to have beneficial effects in reducing ischemia-reperfusion injury. The liposomes complexed to the gene encoding eNOS were infused into the donor coronary circulation before transplantation. This resulted in an inhibition of NF-kB activation, adhesion molecule expression and the early infiltration of leukocytes [23] . Another novel strategy for the treatment of transplant vasculopathy could be the use of NO-donating aspirin (NCX 4040), which has shown beneficial effects on relaxation, cGMP formation and proliferation of vascular smooth muscle cells in vitro [53] .
Finally, acute rejection leads to an activation of iNOS with consequent increases in NO concentrations far beyond the physiologic levels in circulation. NO might have deleterious effects in this setting [1, 7, 40] .
Possible new therapeutic approaches NO-scavenging
Especially concerning iNOS there have been many studies focusing on preventing the induction or inhibiting the activity this enzyme. Moncada's group and others showed that endotoxin and a variety of cytokines induce iNOS in a variety of cell types, including vascular smooth muscle cells [19] . The induction of this enzyme is prevented by various inhibitors of protein synthesis (actinomycin, cycloheximide) and by dexamethasone [27, 45, 48, 54] . Classical inhibitors of the L-arginine pathway such as NG-nitro-Larginine methyl ester (L-NAME) and NG-methyl-Larginine acetate salt (L-NMMA) inhibit both the activity of the inducible enzyme iNOS as well as the activity the constitutive enzymes (eNOS, nNOS). These inhibitors are arginine analogues and principally increase blood pressure and resistance in most vascular beds by inhibiting eNOS and hence reducing basal NO release [16] .
Nitric oxide synthase inhibitors have been evaluated both in experimental models as well as in treatment of patients in septic shock. The results gathered in these studies suggest that inhibiting nitric oxide synthase has many detrimental effects: for instance L-NMMA increased pulmonary vascular resistance and pulmonary artery occlusion pressure considerably and reduced cardiac output and oxygen delivery to the tissues [39] .
L-NMMA increases platelet adhesion to human umbilical vein endothelial cells and platelet accumulation in the lungs induced by administration of interleukin-1b and TNF-a administration [46] . Still, there are approaches, describing beneficial effects of NOS inhibition on contractility after cardiopulmonary bypass [10] . Recently, increased blood concentrations of ADMA (asymmetrical dimethylarginine), an endogenous NO inhibitor, have been linked to increased cardiovascular morbidity and mortality and progression of renal disease. Kielstein et al. showed in healthy subjects, that systemic ADMA or L-NAME infusion induces a short-term, dose-related decrease in cardiac output and a subsequent decrease effective renal plasma flow and blood pressure [25] .
Growing evidence emerged in the past few years that NO produced by iNOS plays a major role in the etiology of organ rejection. Experimental studies showed increased levels of iNOS in rejected myocardium. Clinical studies confirmed these findings [7, 50] . There are two possible therapeutic approaches: scavenging of NO and NOS inhibition.
NOX 100, a nitric oxide scavenger, has shown to enhance cardiac allograft survival [49] . This finding was confirmed using a ruthenium based NO scavenger, AMD6221. This effect was explained by an inhibition of nitrosyl protein complex formation [41] .
Selective inhibition of iNOS by BBS-1 or BBS-2, both allosteric inhibitors of NOS dimerization, showed to be beneficial for allograft survival in a model of acute rejection. Significantly fewer Tlymphocytes and macrophages were observed in the allografts treated. Furthermore, edema formation and cardiomyocyte damage was reduced [59] . Soto et al., who evaluated Aminoguanidine, a selective iNOS inhibitor [55] , confirmed these findings.
However, NO produced by eNOs has been shown be beneficial: inhibition of eNOS by infusion of L-NAME caused a significant increase of intimal thickening in a pig model of heterotopic heart transplantation (HTX) [37] .
NO-substitution
Changes to the vascular endothelium have been identified as a precursor to reperfusion damage leading to a decreased release of NO and organ failure [42, 61] .
Substitution of NO -either providing NO directly or substrates for NO formation -appears to be beneficial in myocardial I/R.
Substitution of substrates of NO synthase
Substitution of L-arginine, the substrate of the NOsynthase, has proven to be beneficial in I/R [52] . In a skeletal muscle model, Huk et al. showed that NO levels increase rapidly during early ischemia but drop dramatically during reperfusion. Treatment with L-arginine prevented this drop in NO production. By providing substrates to the eNOS, uncoupling of the enzyme could be prevented and the pathologic production of superoxides was diminished [20] .
This beneficial effect has been confirmed in experimental models of cardiac transplantation, when L-arginine was added to the cardioplegic or storage solution [9, 43] . Furthermore, clinical studies using L-arginine in cardioplegia during cardiopulmonary bypass supports this data [2, 8] .
Direct NO donors
NO donors increase the bioavailability of NO in the tissue. By direct NO subsititution, endogenous NO synthesis is inhibited, and depletion of L-arginine is prevented. The high L-arginine concentration prevents disarrangement of eNOS and production of superoxide.
Our group is currently evaluating a new NODonor, S-NO-human serum albumin (S-NO-HSA), invented by Seth Hallström and Harald Gasser. This special high molecular weight S-nitrosothiol has an exact equimolar S-nitrosation and high S-nitrosograde due to a defined preprocessing [20] . In an experimental setting of two hours of hind limb ischemia and reperfusion Hallström et al. could show that a substitution of NO during I/R preserves the function of eNOS, stabilizes the basal production of NO, decreases production of reactive oxygen species, and therefore has beneficial effects in reduction of I/R injury [20] . In a second study, a simulation of clinical cold organ procurement and storage, hearts were reperfused after 6 hours of ischemia on an isolated, erythrocyte-perfused working heart model. We could not only show significant beneficial hemodynamic and metabolic effect of S-NO-HSA compared to control, but also compared to a substitution with L-arginine only [51] . In a experimental model of orthotopical heart transplantation in pigs, including 4 hours of ischemia followed by 3 hours of reperfusion, we observed beneficial hemodynamic and metabolic effects of S-NO-HSA compared to control [17] .
Low molecular weight S-nitrosothiols such as S-nitrosoglutathione and S-nitrosocysteine have a short half-life in a range of a few seconds, whereas high molecular weight S-nitrosothiols such as S-nitrosoalbumin shows a prolonged half-life between 15-20 min in vivo [20] .
It has been shown that S-nitroso-N-acetyl-DLpenicillamine induces late preconditioning against myocardial stunning and infarction in rabbits [60] . Snitrosoglutathione monoethyl ester, another Snitroso-thiol, has protective effects in isolated rat hearts during cardioplegic ischemic arrest [28] . Finally, S-nitrosoglutathione inhibits platelet activity during coronary angioplasty [32] and suppresses increased nitric oxide activity (i-NOS) after canine cardiopulmonary bypass [35] . In addition, studies have shown that synthetic compounds such as furoxans require thiols for their thiol-mediated generation of nitric oxide [12] . The substitution of NO is controversially discussed in literature as there are also studies reporting negative effects: This might result from differences of both experimental settings and in NO donors as well as methods of substitution.
In a review published in 2001, R.Bolli concludes that endogenous and exogenous NO is beneficial in protecting the not preconditioned, unstressed heart against damage occurring during ischemia and reperfusion [6] . NO plays a critical bifunctional role in late preconditioning, appearing 12-24 hours after an ischemic stimulus and persisting for 72 h. Enhanced production of NO by eNOS is required to trigger iNOS activity and its anti-stunning and anti-infarct actions of late preconditioning.
In the same review, R. Bolli examined the role of NO in modulating the severity of I/R injury. 73% of the reviewed studies showed that NO either endogenous or exogenous has beneficial effects on myocardial protection against infarction or stunning.
Indirect NO donors
The concept behind the use of angiotensin-converting enzyme (ACE) inhibitors is well understood: ACE is also known as kininase II. This dual enzymatic position explains its dual action: on the one hand the conversion of angiotensin I to angiotensin II is blocked, leading directly to vasorelaxation, on the other hand the breakdown of bradykinin is blocked, leading to an increase in NO with consequent vasodilation [21] . There have been numerous experimental [26, 29, 31] and clinical reports [11, 33] on the beneficial action of ACE inhibitors in the setting of I/R. We have recently reported that even in the failing heart, undergoing I/R, myocardial protection can be significantly improved by pre-ischemic ACE-inhibition. The treated rat hearts showed an improvement in postischemic systolic and diastolic function, coronary perfusion as well as higher levels of high-energy phosphates [44] . However, the direct use of ACE-inhibitors in the setting of HTX is rare.
Sasayama and his group report on the effect of captopril and a selective angiotensin II (AT II) receptor blocker in a murine model of graft sclerosis. Both, the ACE-inhibitor and the AT II receptor blocker were able to reduce chronic allograft rejection compared to control [15] . Perrault et al. demonstrated improved coronary endothelial function with Celsior cardioplegia, a solution with a high antioxidant capacity, compared to standard blood and crystalloid solutions. The authors concluded that this preservation of endotheliumdependent relaxation leads to improvements in both short-and long-term outcome in HTX [38] .
Outlook in donor and recipient management
From our current experience and in the light of literature we would encourage experimental and clinical transplant scientists to take a more holistic approach in organ preservation. This holistic approach should include:
Improvements in donor procurement. Current donor management should be transformed into effective "donor treatment" to recruit more borderline organs safely into the donor pool. The possible role of preischemic NO-substitution (either as substrate, directly or indirectly), should be considered to guarantee a functional endothelium of the graft after implantation.
Optimal perioperative management of the recipient is mandatory. Intra-and perioperative NO-substitution is safe and leads to preserved endothelial function with a reduced chance of acute organ failure and pulmonary hypertension. The beneficial role of this periand postoperative NO-substitution (substrate, direct or indirect) in chronic rejection is already obvious; however it needs to be strengthened by larger clinical trials focusing on the development of microvascular disease.
